Results 61 to 70 of about 999,068 (357)
Virologic Tools for HCV Drug Resistance Testing
Viruses, 2015 Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV
Slim Fourati, Jean-Michel Pawlotsky
doaj +1 more source
Arthritis Care &Research, Accepted Article.Objective We aimed to compare clinical outcomes between patients in the Allegheny Health Network rheumatoid arthritis (RA) care pathway and patients receiving usual care. Methods The care pathway initiative implements guideline‐based best practice alongside multi‐disciplinary team‐based care. Clinical and insurance claims data were extracted to compare
Tarun Sharma +7 more
wiley +1 more source
Hepatitis B discrimination: global responses requiring global data
BMC Public HealthOver 250 million individuals live with chronic hepatitis B (CHB) infection worldwide. A significant proportion of these people often face discrimination defined as the unjust, unfair, or prejudicial treatment of a person on the grounds of their hepatitis
Catherine Freeland +14 more
doaj +1 more source
Adaptive Learning Expert System for Diagnosis and Management of Viral Hepatitis
, 2019 Viral hepatitis is the regularly found health problem throughout the world among other easily transmitted diseases, such as tuberculosis, human immune virus, malaria and so on.
Agizew, Henok Yared
core +2 more sources
Treatments for Hepatitis B [PDF]
Clinical Infectious Diseases, 2004 New optimism surrounds treatments for chronic hepatitis B (CHB). Interferon- alpha , lamivudine, and adefovir dipivoxil are currently approved by the United States Food and Drug Administration for the treatment of CHB. All 3 treatments possess unique characteristics with respect to their side effect profiles, potencies, and treatment niches within the ...
L. D. Saravolatz +5 more
openaire +2 more sources
Advanced Biology, EarlyView.The review provides a critical up‐to‐date overview of the current landscape of human in vitro models for fatty liver disease, including spheroids, organoids, organ‐on‐a‐chip systems, bioprinted liver constructs and precision‐cut liver slices. Their utility for faithfully modeling different stages of MASLD and MASH are evaluated and their compatibility ...
Sonia Youhanna +6 more
wiley +1 more source
Advanced Functional Materials, EarlyView.Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang +9 more
wiley +1 more source
Liver transplantation for viral hepatitis in 2015 [PDF]
, 2016 Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria +8 more
core +1 more source
Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus [PDF]
, 2021 Gang Wang +10 more
openalex +1 more source
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, EarlyView.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source